Accueil / Tag Archives: Research

Tag Archives: Research

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy

Friday, July 21st 2017 at 11:26am UTC Positive opinion based on the results of two randomized Phase 3 trials, TELESTAR and TELECAST PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines …

Plus »

Ipsen reçoit un avis favorable du CHMP à l’octroi d’une AMM pour Xermelo® (télotristat éthyl), dans le traitement de la diarrhée associée au syndrome carcinoïde chez les patients insuffisamment contrôlés par un analogue de la somatostatine

Friday, July 21st 2017 at 11:26am UTC Avis favorable fondé sur les résultats de deux études randomisées de phase 3, TELESTAR et TELECAST PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui que le Comité des médicaments à usage humain (CHMP : Committee for Medicinal Products for …

Plus » étend le marché de la recherche offert aux National Institutes of Health (NIH) des États-Unis

Wednesday, July 19th 2017 at 11:40pm UTC SAN DIEGO–(BUSINESS WIRE)–, la plus importante place de marché mondiale en termes de recherche externalisée, a annoncé aujourd’hui le lancement de l’échange de recherche collaborative NIH (CREx, NIH Collaborative Research Exchange). Créé en partenariat avec le NIH Intramural Research Program (IRP), et …

Plus »

Science Exchange First & Only R&D Outsourcing Platform to Receive EU-U.S. Privacy Shield Framework Certification

Thursday, July 20th 2017 at 1:00pm UTC Privacy Shield Certification Demonstrates Commitment by Science Exchange to Protection and Privacy of Customer Data PALO ALTO, Calif.–(BUSINESS WIRE)– Science Exchange today announced that it is the first and only R&D outsourcing platform to receive EU-U.S. Privacy Shield Framework certification from the U.S. …

Plus »

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

Wednesday, July 19th 2017 at 8:01pm UTC Roclatan™ Successfully Demonstrates a Positive Safety Profile and Efficacy Levels Consistent with Previously Reported Results Conference Call and Webcast Today, July 19, at 5:00 p.m. ET IRVINE, Calif.–(BUSINESS WIRE)– Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and …

Plus »

SpinalCyte, LLC Receives New Japanese Patent

Thursday, July 20th 2017 at 6:12pm UTC HOUSTON–(BUSINESS WIRE)– SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Japanese Patent No. 6151006, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” …

Plus »

InDevR Cypher One™ Collaborative Study With FDA Published

Tuesday, July 18th 2017 at 10:00am UTC InDevR, FDA Study, “Automated interpretation of influenza hemagglutination inhibition (HAI) assays” published in PLOS ONE BOULDER, Colo.–(BUSINESS WIRE)– InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, announced study results and a joint publication with the U.S. Food …

Plus »

Quanterix Boosts Investments in its Accelerator Lab to Support Rapid Growth of Simoa Technology

Tuesday, July 18th 2017 at 8:22pm UTC Dr. Daniel Sikkema joins Quanterix as Vice President of Accelerator Services to lead the growth of the company’s contract research lab and support precision health advances across a wide range of therapeutic categories LEXINGTON, Mass.–(BUSINESS WIRE)– Quanterix Corporation, a company digitizing biomarker analysis …

Plus »

Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting

Monday, July 17th 2017 at 11:00am UTC Compelling unmet need for NAFLD/NASH drug to address estimated $35 billion treatment market by 2025 PETACH TIKVA, Israel–(BUSINESS WIRE)– Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
Retrouvez nous sur
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...